A5054955678- Pulmonary Hypertension Research and Treatments
- COVID-19 Clinical Research Studies
- Cardiovascular Function and Risk Factors
- Long-Term Effects of COVID-19
- Congenital Heart Disease Studies
- SARS-CoV-2 and COVID-19 Research
- Heart Failure Treatment and Management
- Cardiovascular Disease and Adiposity
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Heart rate and cardiovascular health
- Intensive Care Unit Cognitive Disorders
- Respiratory Support and Mechanisms
- Cardiovascular Issues in Pregnancy
- Pneumonia and Respiratory Infections
- Chronic Myeloid Leukemia Treatments
- Transplantation: Methods and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Eosinophilic Disorders and Syndromes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Nuclear reactor physics and engineering
- Thermal Regulation in Medicine
- Mechanical Circulatory Support Devices
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
University of Sheffield
2019-2025
Royal Hallamshire Hospital
2019-2025
Sheffield Teaching Hospitals NHS Foundation Trust
2019-2025
Northern General Hospital
1999-2023
Pulmonary Vascular Research Institute
2020-2022
National Health Service
2020
Sandwell General Hospital
1999
Salisbury University
1999
Aberdeen Royal Infirmary
1999
University of Aberdeen
1999
Rationale: Pulmonary arterial hypertension (PAH) is a life-shortening condition. The European Society of Cardiology and Respiratory the REVEAL (North American Registry to Evaluate Early Long-Term PAH Disease Management) risk score calculator (REVEAL 2.0) identify thresholds predict 1-year mortality.Objectives: This study evaluates whether cardiac magnetic resonance imaging (MRI) can be identified used aid stratification facilitate decision-making.Methods: Consecutive patients with (n = 438)...
Abstract Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that an inadequate response to dual therapy a phosphodiesterase type‐5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended either intensify oral adding selective prostacyclin (IP) agonist (selexipag), or switching from PDE5i soluble guanylate‐cyclase stimulator...
Imatinib 400mg daily reduces pulmonary vascular resistance and improves exercise capacity in patients with arterial hypertension. Concerns about safety tolerability limit its use. To identify a safe tolerated dose of oral imatinib between 100mg evaluate efficacy. Oral was added to the background therapy 17 hypertension, including 13 implanted devices providing measurements cardiopulmonary haemodynamics physical activity. The first patient started on daily. next 12 patients, recruited...
The development of atrial flutter and fibrillation (AFL/AF) in patients with pre-capillary pulmonary hypertension has been associated an increased risk morbidity mortality. Rate rhythm control strategies have not directly compared.Eighty-four arterial (PAH) or chronic thromboembolic (CTEPH) new-onset AFL/AF were identified the ASPIRE registry. First, baseline characteristics rates sinus (SR) restoration 3 arrhythmia management (rate control, medical DC cardioversion, DCCV) early (2009-13)...
Remote monitoring technologies are increasingly used to assess physical activity and cardiopulmonary haemodynamics in patients with pulmonary arterial hypertension (PAH), yet the seasonal stability of these parameters remains poorly defined. In this study, PAH underwent continuous remote using implantable cardiac monitors, artery pressure sensors, smartwatches, structured hospital-based walk tests active passive haemodynamic throughout year. Passively collected data demonstrated significant...
To investigate the outcomes and associated costs of haemodynamic-guided heart failure (HF) management with a pulmonary artery pressure (PAP) sensor in multicentre European cohort.Data from all consecutive patients receiving PAP Ziekenhuis Oost-Limburg, University Hospital Zurich Sheffield Teaching Hospitals NHS Foundation Trust before January 2021 were collected. Medication changes, total number HF hospitalizations related health care (composed hospitalizations, outpatient cardiology visits...
Rationale: Exercise capacity predicts mortality in pulmonary arterial hypertension (PAH), but limited data exist on the routine use of maximal exercise testing.Objectives: This study evaluates a simple-to-perform test (the incremental shuttle walking test) and its risk stratification PAH.Methods: Consecutive patients with were identified from ASPIRE (Assessing Spectrum Pulmonary Identified at REferral centre) registry (2001-2018). Thresholds for levels baseline tested follow-up, their...
Current European Society of Cardiology and Respiratory guidelines recommend regular risk stratification with an aim treating patients pulmonary arterial hypertension (PAH) to improve or maintain low-risk status (<5% 1-year mortality).Consecutive PAH who underwent cardiac magnetic resonance imaging (cMRI) were identified from the Assessing Spectrum Pulmonary Identified at a Referral centre (ASPIRE) registry. Kaplan-Meier survival curves, locally weighted scatterplot smoothing regression...
Abstract In patients with heart failure, guideline directed medical therapy improves outcomes and requires close patient monitoring. Pulmonary artery pressure monitors permit remote assessment of cardiopulmonary haemodynamics facilitate early intervention that has been shown to decrease failure hospitalization. Pressure sensors implanted in the pulmonary vasculature are stabilized through passive or active interaction anatomy communicate an external reader relay invasively measured by...
<h3>Introduction</h3> Remote assessment of real-world physical activity is a potentially important addition in evaluating the effect therapies on how patient "feels, functions and survives". Actigraphy, most used measure activity, an accepted clinical trial endpoint pulmonary arterial hypertension (PAH), with use settings becoming increasingly common. monitoring actigraphy provides high dimensional, data. Despite this, there are challenges adopting as endpoint. One potential under-recognised...
<h3>Aim</h3> To review feasibility and safety of implanting pulmonary artery pressure (PAP) monitors via the right femoral vein (RFV) versus internal jugular (RIJV) in a cohort patients with arterial hypertension (PAH) referred to National PH centre Sheffield. <h3>Background</h3> The implantation PAP is currently licenced RFV during standard heart catheterisation (RHC). Although access RIJV for RHC have been shown be safe, procedures undertaken can quicker, better tolerated significantly...
Background Hospital-based assessment of haemodynamics, exercise capacity and right heart function/strain are used for risk-stratification to aid clinical decision making guide treatment in patients with pulmonary arterial hypertension. Advances haemodynamic cardiac monitoring now provide the remotely measure physiological parameters that relate mortality from a patient’s home. We sought examine remote monitored physiology time preceding following increase standard care therapy worsening...
Background: In patients with pulmonary arterial hypertension (PAH) risk stratification is used to aid clinical decision making and guide treatment categorising as low (<5%), intermediate (5-10%), or high mortality (>10%) at 1 year based on hospital investigations. Risk remote parameters may facilitate early evaluation of efficacy following change indicate stability/deterioration, thereby permitting intervention. Methods: Patients PH were identified from the ASPIRE (6/YH/0352) database...
<h3>Background</h3> Limitation of activity and restriction movement have been widely, effectively, enforced to reduce COVID-19 transmission. Physical is however a critical measure in the prevention cardiovascular disease. Pulmonary arterial hypertension (PAH) devastating, disease driven by small vessel vascular remodeling, leading right heart failure. Exercise capacity relates clinical outcomes exercise training improves key indicators cardiopulmonary function. Here, we describe temporal...
Abstract Background International guidelines recommend regular, hospital-based risk stratification to aid assessment and management of patients with pulmonary arterial hypertension. Technological advances enable daily, remote measurement cardiopulmonary physiology physical activity that have the potential provide early evaluation therapeutic efficacy facilitate intervention based on physiological changes precede clinical events. We sought investigate relationship between remote-monitored...
<h3>Introduction</h3> Hospital-based evaluation of exercise capacity and invasively measured haemodynamics are used for risk-stratification determination therapeutic efficacy in patients with pulmonary arterial hypertension (PAH). Minimally-invasive insertable cardiac monitors (ICM) provide daily, remote measures physiology. To determine the utility monitored physiological measurements risk PAH, we examined HRV, day night heart rate (DHR, NHR) PA an ICM to compare those without clinical...
<h3>Introduction</h3> European guidelines for pulmonary hypertension (PH) recommend comprehensive risk stratification to optimise therapy and achieve/maintain a low profile1,3 using repeated hospital-based investigations undertaken in specialist centres. To facilitate frequent evaluation we sought identify mortality-associated parameters develop score that may be implemented approved remote monitoring technology. <h3>Methods</h3> Consecutive patients (n=5820) with were identified from the...
<h3>Introduction</h3> Pulmonary arterial hypertension (PAH) is a condition driven by endothelial dysfunction and vascular remodelling of the small pulmonary vasculature, causing right-heart failure. In patients with PAH, cardiopulmonary haemodynamics exercise capacity relates to clinical outcomes, training improves function. Public health measures that limit physical activity have been widely enforced reduce COVID-19 transmission. addition, infection causes dysfunction, which central...
<h3>Introduction</h3> European guidelines for pulmonary hypertension (PH) recommend comprehensive risk stratification to optimise therapy and achieve/maintain a low profile using repeated hospital-based investigations undertaken in specialist centres1. Resting heart rate (RHR), total resistance (TPR) physical activity (min/day) are associated with mortality patients PAH. These may be combined provide four-strata remote physiological score (RPS; table 1) use implanted cardiac monitors (ICM)...
<h3>Introduction</h3> Exercise capacity is used for risk stratification in patients with pulmonary arterial hypertension (PAH) and the evaluation of clinical efficacy studies, however, this requires a hospital-based assessment. Physical activity, measured remotely, has been implemented studies as an indicator exercise capacity. The relationships between daily physical activity established measures are unknown. <h3>Methods</h3> Participants PAH enrolled National Cohort Study Idiopathic...
<h3>Introduction</h3> European guidelines for diagnosis and treatment of pulmonary hypertension recommend the use risk stratification to optimise therapy achieve/maintain a low profile.1 The COMPERA 2.0 four strata model is used evaluate following initiation includes assessment of: NT-proBNP, walk distance WHO functional class.2 Physical activity as active minutes/day can be measured remotely using non- or minimally invasive devices. We sought determine any sustained relationship from remote...